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Toxicity assessment is a major challenge in cost-effective drug development, and there is a great need for better tools to accurately predict adverse drug reactions. Technological advances are empowering new cell-based assays for predictive toxicology, and these assays are critically dependent on the cell source. Here, we describe the properties of human induced pluripotent stem (iPS) cells that make them a promising source for toxicity assessment, highlight the progress to date, and point out the important roadblocks that remain.
Current Limitations of PrediCtive toxiCoLogy
Prediction of drug toxicity remains one of the greatest limitations to the efficient development of safe pharmaceuticals and is a major contributor to the high cost of drug development. Although extensive efforts at identifying the toxicity profile of compounds involve the use of a variety of in vitro and animal models before clinical testing, up to 40% of the drugs tested in clinical trials are abandoned because of unanticipated toxic effects. 1 Despite a steady flow of new assays, the success rate in bringing truly novel compounds to market has declined in recent years. Furthermore, adverse drug reactions associated with the use of compounds that are already on the market remain a major cause of morbidity and mortality; some estimates suggest that adverse drug reactions are the fourth most common cause of death in the United States. 2 Therefore, new approaches are urgently needed to improve the efficiency of predictive toxicology.
There are several opportunities for improvement even within the current approach for drug safety assessment. For any safety program required prior to dosing in human subjects, the central components are mandated by regulatory agencies and rely heavily on characterizing toxicity in animals. Animal studies are hampered by several factors, including an imperfect correlation of toxicity patterns between animal models and humans; the costs involved; and a growing pressure to reduce, refine, and replace the use of animals whenever alternative approaches are available. In vitro studies have increasingly been used, especially early in clinical candidate profiling, but their predictive value is inadequate. They are therefore not a suitable replacement for animal studies. This has prompted regulatory agencies to introduce initiatives to improve in vitro toxicity prediction (e.g., parts of the US Food and Drug Administration's Critical Path Initiative and the European Union's Seventh Research Framework Programme) as well as to develop better in vitro assays to evaluate the impact of hazardous compounds in the environment, as recommended by a 2007 National Academy of Science report. 3 However, most existing in vitro assays are substandard because they rely on immortalized cell lines or isolated primary cells (see Table 1 ). Immortalized cell lines are genetically altered, are typically aneuploid, and may exhibit clinically irrelevant toxic responses to compounds. Cells isolated from animal tissues lose their in vivo phenotype, may exhibit high variability from one isolation to the next, and can often be expanded only by dedifferentiation. Species differences will also potentially influence the results. Many of these limitations can be overcome by using human pluripotent stem cells. Readily expandable, karyotypically normal, human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising cell sources for in vitro toxicity assays.
features of iPs CeLLs enabLing in Vitro modeLs
The successful reprogramming of human somatic cells to iPS cells has opened powerful new avenues for predictive in vitro models. 4, 5 iPS cells share many properties with ES cells, including self-renewal and pluripotency. However, the viability of generating iPS cells from a variety of diseased as well as normal human phenotypes gives iPS cells a substantial advantage over ES cells. Access to a theoretically unlimited supply of human iPSderived cells, such as cardiomyocytes, hepatocytes, and neurons, from a diverse population opens the door for powerful genetic and epigenetic experiments that were previously impossible to conduct. Readily obtainable tissues, such as skin, [6] [7] [8] peripheral blood, 9 and other somatic tissues, can be used to generate large libraries of genetically diverse iPS cell lines (Figure 1) . Such PRAc tice iPS libraries can be used for "preclinical" human trials using cell-based assays that would ideally reflect the diversity of drug responses in the population. Second, the feasibility of deriving iPS cells directly from patient samples enables creation of patient-and disease-specific iPS cell lines, which provide powerful in vitro disease models. [6] [7] [8] Disease-specific iPS cell lines not only will enable testing for toxicity but are also likely to be an important tool in the drug discovery process. In addition, the generation of iPS cells from patients who exhibit specific side-effect profiles or idiosyncratic reactions to drugs may prove useful in screening for relatively rare but serious toxic effects. The potential of patient-specific iPS cells to identify patients who would respond adversely or favorably to a drug could provide powerful new approaches for personalized medicine.
deveLoPmentaL toxiCity
Developing human embryos can be highly sensitive to the effects of drugs or chemicals, and the determination of fetal toxicity from maternal exposure to compounds is a key component of toxicity risk assessment. Spontaneous differentiation of mouse ES cells into beating embryoid bodies is currently used by the pharmaceutical industry as an in vitro model to predict teratogenicity. 10 Although other models have been assessed, the mouse embryonic stem cell test has been deemed the most promising assay by the European Centre for the Validation of Alternative Methods. 11 However, recent publications have revealed a substantially lower performance efficiency for this assay, attributed in part to limitations to the training set used by the European Centre for the Validation of Alternative Methods. 12 Although the mouse embryonic stem cell test assay is successful in predicting nondevelopmental toxicants, an area in which improved performance is required is embryotoxic and human-specific teratogens. After a recent reevaluation of the mouse embryonic stem cell test, the integrated project ReProTect recommended new molecular end points and reporter gene approaches. 12, 13 However, the strategy that would perhaps yield most predictive gain would be to integrate new molecular approaches with the use of human ES or iPS cells, thereby avoiding cross-species extrapolation. 14 Recent experiments using figure 1 Generation and utilization of human induced pluripotent stem (iPS) cells in predictive toxicology. Somatic cells from skin, blood, fat, or other tissues can be obtained from consenting donors for transcription factor-based reprogramming to iPS cells. The starting material can provide broad genetic diversity and represent distinct disease phenotypes as well as adverse drug reactions. The iPS cells are differentiated into specific cell lineages that can be characterized in vitro using a wide range of assays for toxicity. 14, 15 Therefore, integration of the advances in our knowledge about human stem cells with recent insights into the molecular aspects of tissue differentiation is a promising approach to improving the ability to assess the risk of human teratogenicity.
HePatotoxiCity
Xenobiotic-induced hepatotoxicity arises from a variety of mechanisms, including reactive metabolites, formation of reactive oxygen species, and inhibition of cytochrome P450 and/or transporter activity. 16, 17 Although nonhepatic cell line models are readily available and expandable, they only vaguely resemble hepatocytes and are suited primarily to assessment of generalized irreversible cytotoxic end points such as cell death. 18 Primary human hepatocytes maintain enough metabolic and functional properties of intact liver to be useful in predictive drug-induced liver injury studies. 18, 19 However, primary human hepatocytes have sporadic and limited accessibility, exhibit high intrinsic variability and phenotypic instability, and display a rapid loss of metabolic functionality once they are placed into culture. 20 Human pluripotent stem cell-derived hepatocytes hold promise for overcoming limitations of primary hepatocyte preparations. Stem cell-derived hepatocytes exhibit cytochrome P450 metabolism, albumin production, glycogen storage, and uptake and excretion of indocyanine green; however, current hepatic differentiation protocols result in cells that have lower levels of enzyme activity as compared with intact human liver. 21 Rapid progress in differentiation protocols and cell culture is likely to provide more functionally robust hepatocytes. Further into the future, hepatocytes from iPS cells generated from specific patients afflicted with idiosyncratic hepatotoxicity may provide insight into the role of genetic diversity in drug-induced injury. Generating panels of iPS cells to reflect the diverse cytochrome P450 profiles seen in the human population will enable studies of human drug metabolism and drug-drug interactions.
CardiotoxiCity
Drug-induced cardiotoxicity takes two primary forms: electrophysiological and biochemical. Electrophysiological toxicities arise when compounds interact with ion channels or transporters to create a proarrhythmic condition in which patients are at increased risk for developing arrhythmias including life-threatening ones such as torsade de pointes. 22 The most common druginduced proarrhythmic condition manifests as an increased QT interval on the surface electrocardiogram, most frequently arising from prolongation of the ventricular action potential through blocking of the human ether-a-go-go channel. 22 However, other ion channels are known to play roles as well. 23, 24 Human pluripotent stem cells can differentiate into functional cardiomyocytes that exhibit hallmark electrophysiological properties such as cardiac action potentials. 25, 26 Although the action potentials are embryonic in phenotype, these cells nonetheless express many of the same ion channels that are present in the adult human heart. Consequently, human stem cell-derived cardiomyocytes can be used to screen for effects of compounds on cardiac ion channels. As predicted, drugs that block L-type Ca 2+ channels shorten the plateau phase of the action potential, whereas compounds that block I Kr prolong the action potential duration (Figure 2a) . There are advantages in using human cardiomyocytes as a screening platform as compared with traditional heterologous expression systems in which single-ion channels are overexpressed. The use of human cardiomyocytes avoids the complications of cross-species translation of results. However, a limitation of current differentiation protocols is that they produce a heterogeneous mixture of cardiomyocyte cell figure 2 Toxicity assays using human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. (a) Electrophysiological toxicity was assayed using the perforated patch clamp technique on single human iPSC-derived cardiomyocytes. action potential duration was shortened by the L-type Ca 2+ channel blocker nifedipine (upper) and prolonged by the human ether-a-go-go K + channel blocker E-4031 (lower). Bars = 100 ms by 20 mV. (b) Biochemical toxicity was assayed by measuring adenosine triphosphate (aTP), reduced glutathione (GSH), and caspase activity using CellTiter, GSH, and Caspase-Glo 3/7 assay kits, respectively, in a 96-well format of cultured iPS cell-derived cardiomyocytes. Imatinib (Gleevec) produced a dose-dependent decrease in cell viability (aTP decrease) and increase in oxidative stress (reduction in GSH) without activating apoptotic pathways (unchanged caspase). PRAc tice types consisting predominantly of ventricular-like cells but also atrial-like and nodal-like cells. 25, 26 Biochemical cardiotoxicity is not as well understood as electrophysiological cardiotoxicity. 27 Anthracyclines such as doxorubicin are anticancer therapeutics that exhibit classical cardiotoxicity through mechanisms that appear to be independent of their DNA-binding ability, potentially through an increase in reactive oxygen species activity. 28 Small-molecule kinase inhibitors are another class of antineoplasm compounds with reported cardiotoxic side effects. 27 Kinase inhibitors target specific and/or multiple kinase pathways that are present in cancerous cells yet show cardiotoxic side effects because many of these same pathways are also expressed in the heart. 27 Human iPS cell-derived cardiomyocytes recapitulate many of the in vivo cardiomyocyte functions and may therefore be an ideal system for assessing multiple facets of toxicity. Figure 2b demonstrates how an application of imatinib (Gleevec) caused a decrease in viability and reduced glutathione levels without inducing caspase-mediated apoptosis. Because the mechanisms underlying cardiotoxicity are poorly understood and often unpredictable, it is imperative that testing be carried out in systems that closely mimic the in vivo condition with appropriate measurable end points. In vivo-like systems would be expected to detect changes in tissue-specific functionality, such as contractility. Native-like cardiotoxicity models employing cardio-specific biomarkers such as the release of cardiac troponin may prove to be more sensitive than the traditional irreversible end points such as adenosine triphosphate or lactate dehydrogenase. 29 Likewise, toxicity of the intended therapeutic target should be examined in a relevant cell system because one needs to know the ability of redundant pathways to compensate for the reduced activity of the targeted pathway and/or the extent to which the unwanted toxicity can be engineered out or overcome. 27 future CHaLLenges and oPPortunities Substantial challenges remain before the full promise of these cells in predictive toxicology can be realized. The technology to generate iPS cells will continue its rapid evolution to facilitate the efficient production of libraries of optimally reprogrammed iPS cells. Although progress has been made in the differentiation protocols, the preparations can vary and may contain heterogeneous mixtures of cell types. Therefore, the refining of protocols to obtain the desired cell type will continue to be a focus of efforts such as those involving the use of tissue-and lineagespecific promoters coupled with antibiotic-resistance genes. 30 Likewise, the advent of differentiation protocols directed toward other adult cell types such as spleen and kidney will broaden the landscape of potential toxicity assays. However, the relative maturity of the iPS cell-derived cell lineages remains a potential limitation, given that most cell types maintain a more embryonic phenotype in culture. Future efforts to combine various cell types and construct complex tissue and organ models for testing may prove to be particularly fruitful.
ConCLusions
Utilizing human iPS cell-derived cell lineages early in the drug development pipeline holds promise for enabling early, rapid, and more comprehensive toxicity screening across general populations as well as in targeted and at-risk populations as compared with current technologies. There remain substantial challenges before the full promise of iPS cells for predictive toxicology can be realized. These include determining more effective ways to differentiate cells to the desired lineage or tissue constructs and optimizing assays with these preparations. The progress achieved using iPS cell-derived cardiomyocytes and hepatocytes is beginning to validate this approach for the two most common areas of toxicity encountered in drug development. Ultimately, using iPS-cell derivatives throughout the drug discovery pipeline can be expected to reduce late-phase compound attrition, thereby saving on costs and enhancing consumer safety. ConfLiCt of interest T.J.K. is a cofounder of and consultant for Cellular Dynamics International, a company that performs toxicity testing with cellular products derived from human iPS cells. The other authors declared no conflict of interest.
